Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03376321 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Hospitalized Participants With Influenza A Infection
A Phase 3 study, sponsored by Janssen Research & Development.
- Terminated
- Registry status
- Phase 3
- Development phase
- 334
- Enrollment target
NCT03376321 is a Phase 3 study that was terminated before completion, run by Janssen Research & Development. The registered enrollment target is 334 participants.
The verdict
NCT03376321, a Phase 3 study, was terminated before completion, sponsored by Janssen Research & Development.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 334 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the clinical and virologic benefit of pimodivir in combination with Standard-of-Care (SOC) treatment compared to placebo in combination with SOC treatment.
Interventions
- DRUG Placebo
- DRUG Pimodivir 600 mg
- OTHER SOC Treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 334 participants |
| Start Date | 2018-01-03 |
| Est. Completion | 2020-04-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03376321
The ClinicalTrials.gov registry entry for NCT03376321 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 334 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03376321 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03376321 about?
NCT03376321 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Hospitalized Participants With Influenza A Infection". The purpose of this study is to evaluate the clinical and virologic benefit of pimodivir in combination with Standard-of-Care (SOC) treatment compared to placebo in combination with SOC treatment.
What is the current status of trial NCT03376321?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 334 participants. The study started on 2018-01-03. Estimated completion is 2020-04-30.
What interventions are being tested in trial NCT03376321?
The interventions under investigation include: Placebo (DRUG), Pimodivir 600 mg (DRUG), SOC Treatment (OTHER).
Who is sponsoring clinical trial NCT03376321?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.